Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study

Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide

(2018) V. Guarnotta et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial

(2018) André Lacroix et al.   Lancet Diabetes & Endocrinology

Complications of Cushing's syndrome: state of the art

(2016) Rosario Pivonello et al.   Lancet Diabetes & Endocrinology

The Treatment of Cushing's Disease

(2015) Rosario Pivonello et al.   ENDOCRINE REVIEWS

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline

(2015) Lynnette K. Nieman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cushing's syndrome

(2015) André Lacroix et al.   LANCET

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

(2014) Rosario Pivonello et al.   CLINICAL ENDOCRINOLOGY

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

(2014) A. Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial

(2014) Jochen Schopohl et al.   Pituitary

Update on radiation therapy in patients with Cushing’s disease

(2014) Nicholas A. Tritos et al.   Pituitary

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

(2014) Mônica R Gadelha et al.   Lancet Diabetes & Endocrinology

Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers

(2013) Robert R. Henry et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III Trial

(2013) Jessica MacKenzie Feder et al.   Pituitary

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations

(2013) Annamaria Colao et al.   Pituitary

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

(2012) Annamaria Colao et al.   NEW ENGLAND JOURNAL OF MEDICINE